Moderna, Inc. Common Stock (MRNA) stock analysis and AI prediction
The company facts of Moderna, Inc. Common Stock, with its price and AI prediction for the next 10 market days in SharePreds.
Keep looking in SharePreds
You have looked at today's stocks on this website. SharePreds shows every stock's likelihood of rising, its chart and how its earlier predictions ended, with alerts on the ones you follow.
See all five apps
About Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Sector
- Healthcare
- Exchange
- NASDAQ
- Market value
- $93.6 billion
- Size
- Large cap
- Employees
- 4,700
- Headquarters
- CAMBRIDGE, MA
- Listed since
- Dec. 7, 2018
- Website
- modernatx.com
More Healthcare stocks
Other large cap stocks
Keep going
MRNA questions
What is the AI prediction for MRNA stock?
Each market day our model rates Moderna, Inc. Common Stock (MRNA) Bullish, Neutral or Bearish for the next 10 market days. Predictions are indicative: they rest on price and volume data, and they can be wrong.
How often is the MRNA prediction updated?
Each market day, Monday to Friday, except market holidays. The date of the prediction is shown beside it.
What do Bullish, Neutral and Bearish mean?
Bullish means the model sees a rise as likely over the next 10 market days, Bearish a fall, and Neutral no clear direction.
Where can I see the exact likelihood for MRNA?
In the SharePreds app for iPhone and Android, with the stock's chart, alerts on it and how its earlier predictions ended.
Where can I see MRNA options?
The MRNA options page opens its calls and puts, with price, volume, implied volatility and the Greeks.